Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO)

NCT00109187 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00109187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00109187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Extension Study II of Xolair (Omalizumab) in Moderate to Severe, Persistent Asthma Subjects Who Completed Study Q2143g (ALTO)
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2002
Completion date
April 30, 2003
Enrollment
0
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

asthma